Loading...
•
Sep 30, 2021
Novavax Q3 2021 Earnings Report
Announced financial results for the third quarter ended September 30, 2021.
Key Takeaways
Novavax reported revenue of $178.8 million and a net loss of $322.4 million, or $4.31 per share, for the third quarter of 2021.
Gained first regulatory approval for COVID-19 vaccine.
Prepared to deliver vaccine globally with additional regulatory submissions.
Encouraging results from six-month booster study complement strong efficacy demonstrated by NVX-CoV2373.
Confident that vaccine will serve as an important tool to fight COVID-19 in the years to come.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...